ULTIMOVACS ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.7 NOK | -5.13% |
|
+15.23% | -92.92% |
| 06-11 | Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma | CI |
| 05-07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 29.39M | - | - | - | - | - | |
| 56.87B | - | |||||
| 39.72B | ||||||
| 39.27B | ||||||
| 28.73B | ||||||
| 26.21B |
- Stock Market
- Equities
- ULTI Stock
- Charts Ultimovacs ASA
- Sector Chart